Addressing Current Challenges in Preventing and Managing

Neutropenia in Cancer

Program goals

Neutropenia Overview

Febrile Neutropenia

Myeloid Growth Factors

Adverse Effects of Filgrastim and Derivatives

Tbo-filgrastim

Prevention of Febrile Neutropenia With CSFs

Assess Risk from Chemotherapy Regimen

Prevention of Febrile Neutropenia With CSFs

Assess Patient Risk Factors

Developing a Model to Assess Risk

Administration Issues

Pharmacoeconomic Considerations

Agent Specifics

Summary

Abbreviations

References

References (cont)

References (cont)